NASDAQ:DXR Daxor (DXR) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free DXR Stock Alerts $8.89 +0.32 (+3.73%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$8.40▼$8.8950-Day Range$7.19▼$10.0352-Week Range$7.11▼$13.13Volume6,454 shsAverage Volume3,505 shsMarket Capitalization$42.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsShort InterestSocial Media Get Daxor alerts: Email Address Ad DTIHow you can target big results without spending big money!While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades! Click here so I can share the details of my $0.25 Cent Trades About Daxor Stock (NASDAQ:DXR)Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.Read More DXR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXR Stock News HeadlinesMarch 25, 2024 | globenewswire.comDaxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of DiagnosticsMarch 24, 2024 | americanbankingnews.comDaxor (DXR) to Release Quarterly Earnings on MondayMarch 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 22, 2024 | globenewswire.comDaxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024March 18, 2024 | globenewswire.comDaxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023March 18, 2024 | globenewswire.comDaxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to ShareholdersMarch 11, 2024 | globenewswire.comDaxor Announces Sales to Three New Hospitals Furthering Expansion of Its User BaseMarch 8, 2024 | globenewswire.comMulti-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure PatientsMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…February 26, 2024 | globenewswire.comDaxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics ConferenceSee More Headlines Receive DXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:DXR CUSIPN/A CIK27367 Webwww.daxor.com Phone212-244-0555Fax212-244-0806EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,740,000Free Float1,866,000Market Cap$40.62 million OptionableNot Optionable Beta-0.49 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael Richard Feldschuh (Age 55)Chairman, President & CEO Comp: $100kMr. Jonathan Adam Feldschuh (Age 59)Chief Scientific Officer & Director Comp: $127.92kMr. Robert J. Michel CPA (Age 67)CPA, M.B.A., CFO, Chief Compliance Officer & Corporate Secretary Ms. Linda CooperVice President of Development & OperationsMs. Kathryn A. KornafelSenior VP of Marketing & Commercial DevelopmentMr. Guido ManzoVice President of SalesMs. Jean OertelSenior Vice President Commercialization & Customer ExperienceMore ExecutivesKey CompetitorsDarioHealthNASDAQ:DRIOLENSARNASDAQ:LNSRSpectral AINASDAQ:MDAICo-DiagnosticsNASDAQ:CODXRetractable TechnologiesNYSE:RVPView All CompetitorsInsidersRobert J MichelBought 750 shares on 3/27/2024Total: $6,525.00 ($8.70/share)Michael Richard FeldschuhBought 800 shares on 12/1/2023Total: $6,240.00 ($7.80/share)Robert J MichelBought 180 shares on 12/1/2023Total: $1,395.00 ($7.75/share)Robert J MichelBought 500 shares on 11/24/2023Total: $3,970.00 ($7.94/share)Michael Richard FeldschuhBought 401 shares on 11/9/2023Total: $3,147.85 ($7.85/share)View All Insider Transactions DXR Stock Analysis - Frequently Asked Questions How have DXR shares performed in 2024? Daxor's stock was trading at $9.60 at the beginning of the year. Since then, DXR stock has decreased by 7.4% and is now trading at $8.89. View the best growth stocks for 2024 here. Are investors shorting Daxor? Daxor saw a increase in short interest in March. As of March 15th, there was short interest totaling 8,100 shares, an increase of 9.5% from the February 29th total of 7,400 shares. Based on an average daily trading volume, of 3,000 shares, the days-to-cover ratio is currently 2.7 days. Approximately 0.4% of the company's shares are short sold. View Daxor's Short Interest. What other stocks do shareholders of Daxor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Merck & Co., Inc. (MRK), Novavax (NVAX), Arbutus Biopharma (ABUS), Abbott Laboratories (ABT), Abiomed (ABMD), Aclaris Therapeutics (ACRS), AngloGold Ashanti (AU), Bellicum Pharmaceuticals (BLCM). How do I buy shares of Daxor? Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DXR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.